These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32332615)

  • 1. Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT Compliant).
    Morioka I; Kakei Y; Omori T; Nozu K; Fujioka K; Yoshikawa T; Moriuchi H; Ito Y; Oka A
    Medicine (Baltimore); 2020 Apr; 99(17):e19765. PubMed ID: 32332615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of patients' characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease.
    Kakei Y; Morioka I; Imai T; Itohara K; Yano I; Takahashi N; Yoshikawa T; Moriuchi H; Ito Y; Fujioka K; Oka A;
    J Infect Chemother; 2024 Oct; 30(10):971-977. PubMed ID: 38484931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan.
    Morioka I; Kakei Y; Omori T; Nozu K; Fujioka K; Takahashi N; Yoshikawa T; Moriuchi H; Ito Y; Oka A;
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection.
    Ohyama S; Morioka I; Fukushima S; Yamana K; Nishida K; Iwatani S; Fujioka K; Matsumoto H; Imanishi T; Nakamachi Y; Deguchi M; Tanimura K; Iijima K; Yamada H
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of poor neurological development in patients with symptomatic congenital cytomegalovirus diseases after oral valganciclovir treatment.
    Fukushima S; Morioka I; Ohyama S; Nishida K; Iwatani S; Fujioka K; Mandai T; Matsumoto H; Nakamachi Y; Deguchi M; Tanimura K; Iijima K; Yamada H
    Brain Dev; 2019 Oct; 41(9):743-750. PubMed ID: 31072632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term hearing outcomes of children with symptomatic congenital CMV treated with valganciclovir.
    McCrary H; Sheng X; Greene T; Park A
    Int J Pediatr Otorhinolaryngol; 2019 Mar; 118():124-127. PubMed ID: 30611098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection.
    Suganuma E; Sakata H; Adachi N; Asanuma S; Furuichi M; Uejima Y; Sato S; Abe T; Matsumoto D; Takahashi R; Yamamoto S; Kawano Y; Arai T; Oh-Ishi T
    J Infect Chemother; 2021 Feb; 27(2):185-191. PubMed ID: 32907793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Multifaceted Clinical Characteristics of Congenital Cytomegalovirus Infection: From Pregnancy to Long-Term Outcomes.
    Kim Y; Kim YM; Kim DR; Kim HG; Sung JH; Choi SJ; Oh SY; Kim YJ; Chang YS; Kim D; Kim JS; Moon IJ; Roh CR
    J Korean Med Sci; 2023 Aug; 38(32):e249. PubMed ID: 37582499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.
    Meine Jansen CF; Toet MC; Rademaker CM; Ververs TF; Gerards LJ; van Loon AM
    J Perinat Med; 2005; 33(4):364-6. PubMed ID: 16211780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness.
    Bourgon N; Lopez R; Fourgeaud J; Guilleminot T; Bussières L; Magny JF; Ville Y; Leruez Ville M
    J Antimicrob Chemother; 2024 Oct; 79(10):2500-2508. PubMed ID: 39087737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening.
    Kawada J; Torii Y; Kawano Y; Suzuki M; Kamiya Y; Kotani T; Kikkawa F; Kimura H; Ito Y
    J Clin Virol; 2015 Apr; 65():41-5. PubMed ID: 25766986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial.
    Kimberlin DW; Aban I; Peri K; Nishikawa JK; Bernatoniene J; Emonts M; Klein N; Bamford A; DeBiasi RL; Faust SN; Jones CE; McMaster P; Caserta M; Ahmed A; Sharland M; Demmler-Harrison G; Hackett S; Sánchez PJ; Shackley F; Kelly D; Dennehy PH; Storch GA; Whitley RJ; Griffiths P;
    J Pediatr; 2024 May; 268():113934. PubMed ID: 38309519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant.
    Müller A; Eis-Hübinger AM; Brandhorst G; Heep A; Bartmann P; Franz AR
    J Perinatol; 2008 Jan; 28(1):74-6. PubMed ID: 18165832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial.
    Rojo P; Moraleda C; Tagarro A; Domínguez-Rodríguez S; Castillo LM; Tato LMP; López AS; Manukyan L; Marcy O; Leroy V; Nardone A; Burger D; Bassat Q; Bates M; Moh R; Iroh Tam PY; Mvalo T; Magallhaes J; Buck WC; Sacarlal J; Musiime V; Chabala C; Mujuru HA
    Trials; 2022 Jun; 23(1):531. PubMed ID: 35761406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
    Togashi J; Sugawara Y; Hashimoto M; Tamura S; Kaneko J; Aoki T; Hasegawa K; Kokudo N
    Biosci Trends; 2011; 5(5):217-22. PubMed ID: 22101378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cohort study of the universal neonatal urine screening for congenital cytomegalovirus infection.
    Yamada H; Tanimura K; Fukushima S; Fujioka K; Deguchi M; Sasagawa Y; Tairaku S; Funakoshi T; Morioka I
    J Infect Chemother; 2020 Aug; 26(8):790-794. PubMed ID: 32273174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment.
    Nishida K; Morioka I; Nakamachi Y; Kobayashi Y; Imanishi T; Kawano S; Iwatani S; Koda T; Deguchi M; Tanimura K; Yamashita D; Nibu K; Funakoshi T; Ohashi M; Inoue N; Iijima K; Yamada H
    Brain Dev; 2016 Feb; 38(2):209-16. PubMed ID: 26282917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients.
    Shaikh S; Jasiak-Panek N; Park JM
    Clin Transplant; 2018 Sep; 32(9):e13369. PubMed ID: 30076649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation.
    Misaki Y; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Yoshimura K; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
    Transpl Infect Dis; 2020 Jun; 22(3):e13270. PubMed ID: 32092224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.